1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Pandemic Influenza - Pipeline Review, H2 2014

Pandemic Influenza - Pipeline Review, H2 2014

  • July 2014
  • -
  • Global Markets Direct
  • -
  • 146 pages

Pandemic Influenza - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Pandemic Influenza - Pipeline Review, H2 2014’, provides an overview of the Pandemic Influenza’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pandemic Influenza, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pandemic Influenza and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pandemic Influenza
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pandemic Influenza and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pandemic Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pandemic Influenza pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pandemic Influenza
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pandemic Influenza pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Pandemic Influenza - Pipeline Review, H2 2014
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Pandemic Influenza Overview 8
Therapeutics Development 9
Pipeline Products for Pandemic Influenza - Overview 9
Pipeline Products for Pandemic Influenza - Comparative Analysis 10
Pandemic Influenza - Therapeutics under Development by Companies 11
Pandemic Influenza - Therapeutics under Investigation by Universities/Institutes 15
Pandemic Influenza - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Pandemic Influenza - Products under Development by Companies 20
Pandemic Influenza - Products under Investigation by Universities/Institutes 22
Pandemic Influenza - Companies Involved in Therapeutics Development 23
Johnson and Johnson 23
Autoimmune Technologies, LLC 24
GlaxoSmithKline plc 25
MedImmune, LLC 26
Emergent BioSolutions Inc. 27
Lentigen Corporation 28
Takeda Pharmaceutical Company Limited 29
Celltrion, Inc. 30
Novartis AG 31
Novavax, Inc. 32
OPKO Health, Inc. 33
Medicago Inc. 34
BioDiem Ltd 35
TechnoVax, Inc. 36
PDS Biotechnology Corporation 37
Theraclone Sciences, Inc. 38
Sinovac Biotech Ltd. 39
NanoBio Corporation 40
Protein Sciences Corporation 41
Immunovaccine, Inc. 42
VaxInnate Corporation 43
UMN Pharma Inc. 44
Sirnaomics, Inc. 45
AIMM Therapeutics B.V. 46
Cilian AG 47
AmVac AG 48
TSRL, Inc. 49
AltraVax Inc. 50
Big DNA Ltd. 51
ContraFect Corporation 52
PeptiVir, Inc. 53
Pike Pharma GmbH 54
Codagenix, Inc. 55
Pandemic Influenza - Therapeutics Assessment 56
Assessment by Monotherapy Products 56
Assessment by Combination Products 57
Assessment by Target 58
Assessment by Mechanism of Action 60
Assessment by Route of Administration 62
Assessment by Molecule Type 64
Drug Profiles 66
KIB-PCI - Drug Profile 66
Live Attenuated Influenza Vaccine - Drug Profile 67
UMN-0501 - Drug Profile 69
Subunit Vaccine for H5N1 Influenza - Drug Profile 71
TCN-032 - Drug Profile 72
CTP-27 - Drug Profile 74
VX-787 - Drug Profile 75
Pandemic Influenza Vaccine [H5N1] - Drug Profile 76
Pandemic Influenza Vaccine [H7N9] (Monovalent) - Drug Profile 77
MEDI-550 - Drug Profile 79
flu pandemic (H5N1) vaccine - Drug Profile 80
VAX-161 - Drug Profile 81
VAX-16101C - Drug Profile 82
MEDI-9287 - Drug Profile 83
Vaccine for H7N9 Influenza - Drug Profile 84
Flu Vaccine - Drug Profile 85
LG-611 - Drug Profile 86
Subunit Vaccine for H5N1 Pandemic Influenza - Drug Profile 87
STP-702 - Drug Profile 88
TVX-002 - Drug Profile 89
Influenza VLP Vaccine - Drug Profile 90
MVA-H5HA - Drug Profile 91
Flufirvitide-3 - Drug Profile 92
Anti-H5HA mAB - Drug Profile 93
Monoclonal Antibodies to Target Hemagglutinin for Seasonal Influenza and Pandemic Influenza - Drug Profile 94
CF-404 - Drug Profile 95
Pandemic Influenza Vaccine - Drug Profile 96
AMV-411 - Drug Profile 97
CiFlu - Drug Profile 98
Bispecific Monoclonal Antibody for Seasonal and Pandemic Influenza - Drug Profile 100
UMN-0901 - Drug Profile 101
TSR-026 - Drug Profile 102
PDS-0102 - Drug Profile 103
Pandemic Influenza Vaccine - Drug Profile 104
IKT-041 - Drug Profile 105
Pandemic Influenza Vaccine - Drug Profile 106
H7N9 VLP Vaccine + Glucopyranosyl Lipid A Adjuvant - Drug Profile 107
PVI-1000 - Drug Profile 108
A-06 - Drug Profile 109
BDNA-002 - Drug Profile 110
LIAVM-2eHD - Drug Profile 111
Pan-Flu - Drug Profile 113
Pandemic Influenza Vaccine - Drug Profile 114
CTP-25 - Drug Profile 115
Universal Vaccine for Seasonal and Pandemic Influenza - Drug Profile 116
TSR-462 - Drug Profile 117
Monoclonal Antibodies to Inhibit Hemagglutinin for Pandemic Influenza - Drug Profile 118
Small Molecules to Inhibit Viral Polymerase for Influenza - Drug Profile 119
Pandemic Infleunza Vaccine - Drug Profile 120
Vaccine for Pandemic Influenza - Drug Profile 121
Vaccine for Pandemic Influenza - Drug Profile 122
Pandemic Influenza - Recent Pipeline Updates 123
Pandemic Influenza - Dormant Projects 133
Pandemic Influenza - Product Development Milestones 134
Featured News and Press Releases 134
Appendix 141
Methodology 141
Coverage 141
Secondary Research 141
Primary Research 141
Expert Panel Validation 141
Contact Us 142
Disclaimer 142

List of Tables

Number of Products under Development for Pandemic Influenza, H2 2014 13
Number of Products under Development for Pandemic Influenza - Comparative Analysis, H2 2014 14
Number of Products under Development by Companies, H2 2014 16
Number of Products under Development by Companies, H2 2014 (Contd..1) 17
Number of Products under Development by Companies, H2 2014 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H2 2014 19
Comparative Analysis by Late Stage Development, H2 2014 20
Comparative Analysis by Clinical Stage Development, H2 2014 21
Comparative Analysis by Early Stage Development, H2 2014 22
Comparative Analysis by Unknown Stage Development, H2 2014 23
Products under Development by Companies, H2 2014 24
Products under Development by Companies, H2 2014 (Contd..1) 25
Products under Investigation by Universities/Institutes, H2 2014 26
Pandemic Influenza - Pipeline by Johnson and Johnson, H2 2014 27
Pandemic Influenza - Pipeline by Autoimmune Technologies, LLC, H2 2014 28
Pandemic Influenza - Pipeline by GlaxoSmithKline plc, H2 2014 29
Pandemic Influenza - Pipeline by MedImmune, LLC, H2 2014 30
Pandemic Influenza - Pipeline by Emergent BioSolutions Inc., H2 2014 31
Pandemic Influenza - Pipeline by Lentigen Corporation, H2 2014 32
Pandemic Influenza - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 33
Pandemic Influenza - Pipeline by Celltrion, Inc., H2 2014 34
Pandemic Influenza - Pipeline by Novartis AG, H2 2014 35
Pandemic Influenza - Pipeline by Novavax, Inc., H2 2014 36
Pandemic Influenza - Pipeline by OPKO Health, Inc., H2 2014 37
Pandemic Influenza - Pipeline by Medicago Inc., H2 2014 38
Pandemic Influenza - Pipeline by BioDiem Ltd, H2 2014 39
Pandemic Influenza - Pipeline by TechnoVax, Inc., H2 2014 40
Pandemic Influenza - Pipeline by PDS Biotechnology Corporation, H2 2014 41
Pandemic Influenza - Pipeline by Theraclone Sciences, Inc., H2 2014 42
Pandemic Influenza - Pipeline by Sinovac Biotech Ltd., H2 2014 43
Pandemic Influenza - Pipeline by NanoBio Corporation, H2 2014 44
Pandemic Influenza - Pipeline by Protein Sciences Corporation, H2 2014 45
Pandemic Influenza - Pipeline by Immunovaccine, Inc., H2 2014 46
Pandemic Influenza - Pipeline by VaxInnate Corporation, H2 2014 47
Pandemic Influenza - Pipeline by UMN Pharma Inc., H2 2014 48
Pandemic Influenza - Pipeline by Sirnaomics, Inc., H2 2014 49
Pandemic Influenza - Pipeline by AIMM Therapeutics B.V., H2 2014 50
Pandemic Influenza - Pipeline by Cilian AG, H2 2014 51
Pandemic Influenza - Pipeline by AmVac AG, H2 2014 52
Pandemic Influenza - Pipeline by TSRL, Inc., H2 2014 53
Pandemic Influenza - Pipeline by AltraVax Inc., H2 2014 54
Pandemic Influenza - Pipeline by Big DNA Ltd., H2 2014 55
Pandemic Influenza - Pipeline by ContraFect Corporation, H2 2014 56
Pandemic Influenza - Pipeline by PeptiVir, Inc., H2 2014 57
Pandemic Influenza - Pipeline by Pike Pharma GmbH, H2 2014 58
Pandemic Influenza - Pipeline by Codagenix, Inc., H2 2014 59
Assessment by Monotherapy Products, H2 2014 60
Assessment by Combination Products, H2 2014 61
Number of Products by Stage and Target, H2 2014 63
Number of Products by Stage and Mechanism of Action, H2 2014 65
Number of Products by Stage and Route of Administration, H2 2014 67
Number of Products by Stage and Molecule Type, H2 2014 69
Pandemic Influenza Therapeutics - Recent Pipeline Updates, H2 2014 127
Pandemic Influenza - Dormant Projects, H2 2014 137

List of Figures

Number of Products under Development for Pandemic Influenza, H2 2014 13
Number of Products under Development for Pandemic Influenza - Comparative Analysis, H2 2014 14
Number of Products under Development by Companies, H2 2014 15
Comparative Analysis by Clinical Stage Development, H2 2014 21
Comparative Analysis by Early Stage Products, H2 2014 22
Assessment by Monotherapy Products, H2 2014 60
Number of Products by Top 10 Target, H2 2014 62
Number of Products by Stage and Top 10 Target, H2 2014 63
Number of Products by Top 10 Mechanism of Action, H2 2014 64
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 65
Number of Products by Top 10 Route of Administration, H2 2014 66
Number of Products by Stage and Top 10 Route of Administration, H2 2014 67
Number of Products by Top 10 Molecule Type, H2 2014 68
Number of Products by Stage and Top 10 Molecule Type, H2 2014 69

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Influenza Diagnostics Market By Test Type, By End Use and Segment Forecasts to 2024

Influenza Diagnostics Market By Test Type, By End Use and Segment Forecasts to 2024

  • $ 4950
  • Industry report
  • September 2016
  • by Grand View Research

The influenza diagnostics market is expected to reach USD 3.3 billion by 2024, according to a new report by Grand View Research, Inc. Influenza, or "the flu," is an infectious disease and affects the uppe ...

H1N1 (Swine Influenza)- Market Insights, Epidemiology and Market Forecast-2023

H1N1 (Swine Influenza)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s H1N1 (Swine Influenza) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Influenza Diagnostics Market By Test Type (Rapid Influenza Diagnostic Test [RIDT], Reverse Transcription Polymerase Chain Reaction[RT-PCR], Cell Culture, Others - Immunofluorescence, Serology), By End Use, And Segment Forecasts To 2024

Influenza Diagnostics Market By Test Type (Rapid Influenza Diagnostic Test [RIDT], Reverse Transcription Polymerase Chain Reaction[RT-PCR], Cell Culture, Others - Immunofluorescence, Serology), By End Use, And Segment Forecasts To 2024

  • $ 4950
  • Industry report
  • September 2016
  • by Grand View Research

The influenza diagnostics market is expected to reach USD 3.3 billion by 2024, according to a new report by Grand View Research, Inc. Influenza, or "the flu," is an infectious disease and affects the uppe ...


Download Unlimited Documents from Trusted Public Sources

Infectious Disease Statistics in the US

  • December 2016
    32 pages
  • Infectious Dise...  

    Asthma  

  • United States  

View report >

The future of the Vaccine Industry in the UK

  • December 2016
    2 pages
  • Vaccine  

    Infectious Dise...  

  • United Kingdom  

View report >

Infectious Disease Statistics in Brazil

  • December 2016
    9 pages
  • Infectious Dise...  

    Hospital  

  • Brazil  

View report >

Related Market Segments :

Influenza
Vaccine
Therapy

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.